Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life

Authors Marc Miravitlles, Carles Llor, Jesús Molina, et al

Published Date January 2010 Volume 2010:5 Pages 11—19

DOI http://dx.doi.org/10.2147/COPD.S8732

Published 15 January 2010

Marc Miravitlles1, Carles Llor2, Jesús Molina3, Karlos Naberan4, Josep M Cots5, Fernando Ros6 on behalf of the EVOCA Study Group

1Fundació Clínic. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Primary Health Care Center ‘Jaume I’, Societat Catalana de Medicina Familiar i Comunitària, Universitat Rovira i Virgili, Tarragona, Spain; 3Primary Health Care Center ‘Francia’, Grupo de Respiratorio de la Sociedad Madrileña de Medicina Familiar y Comunitaria, Madrid, Spain; 4Primary Health Care Center ‘Fuentes de Ebro’, Grupo de Investigación del Instituto Aragonés Ciencias de la Salud (IACS), Zaragoza, Spain; 5Primary Health Care Center ‘La Marina’, Societat Catalana de Medicina Familiar i Comunitària, Facultat de Medicina, Barcelona, Spain; 6Medical Department, Bayer Healthcare, Barcelona, Spain

Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) of patients with COPD and to compare the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day for 10 days) on HRQL.

Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV1 % predicted 49.3%) participated in a prospective, observational study of 2 years’ duration. The St George’s Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.

Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and “Symptoms” subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients with two or more exacerbations.

Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more favorable long-term effect on quality of life than amoxicillin/clavulanate.
Keywords: COPD, exacerbations, moxifloxacin, amoxicillin/clavulanate, quality of life, SGRQ

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 15 September 2008

Readers of this article also read:

Efficacy and feasibility of the immunomagnetic separation based diagnosis for detecting sentinel lymph node metastasis from breast cancer

Zhi XC, Zhang M, Meng TT, Zhang XB, Shi ZD, Liu Y, Liu JJ, Zhang S, Zhang J

International Journal of Nanomedicine 2015, 10:2775-2784

Published Date: 7 April 2015

Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells

Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, Wang Z, Huang L

International Journal of Nanomedicine 2015, 10:2461-2473

Published Date: 27 March 2015

Docetaxel-loaded solid lipid nanoparticles as a basis for a targeted and dose-sparing personalized breast cancer treatment strategy

Danilova NV, Kalzhanov ZR, Nefedova NA, Mal’kov PG, Kosmas IP, Eliseeva MY, Mynbaev OA

International Journal of Nanomedicine 2015, 10:2417-2421

Published Date: 25 March 2015

Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy

Taratula O, Patel M, Schumann C, Naleway MA, Pang AJ, He H, Taratula O

International Journal of Nanomedicine 2015, 10:2347-2362

Published Date: 24 March 2015

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab

Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K

International Journal of Nanomedicine 2015, 10:2173-2190

Published Date: 18 March 2015

Molecular photoacoustic imaging of breast cancer using an actively targeted conjugated polymer

Balasundaram G, Ho CJH, Li K, Driessen WH, Dinish US, Wong CL, Ntziachristos V, Liu B, Olivo M

International Journal of Nanomedicine 2015, 10:387-397

Published Date: 8 January 2015

Effect of zinc oxide nanoparticles on dams and embryo–fetal development in rats

Hong J, Park M, Kim M, Lim J, Park G, Meang E, Shin J, Kim Y, Kim M, Lee J, Park J, Kim J, Shin H

International Journal of Nanomedicine 2014, 9:145-157

Published Date: 15 December 2014

Management of COPD in general practice in Denmark – participating in an educational program substantially improves adherence to guidelines

Charlotte Suppli Ulrik, Ejvind Frausing Hansen, Michael Skov Jensen, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:73-79

Published Date: 11 March 2010